Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
As posted on ClinicalTrials.gov (NCT02963935), updated at source Mar 11, 2020. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | -7.4(7.9) | -4.0(7.4) |
| On-drug observation period | -9.1(7.4) | -4.8(7.6) |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 61.47 | 38.82 |
| On-drug observation period | 64.08 | 38.57 |
Percent of participants affected, From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.. The most common events the registry lists.
| Event | Lira 3.0 mg | Placebo |
|---|---|---|
| Any serious event | 4.2% | 1.4% |
| Nausea | 47.9% | 17.9% |
| Constipation | 30.3% | 18.6% |
| Vomiting | 23.2% | 5% |
| Upper respiratory tract infection | 22.5% | 10.7% |
| Diarrhoea | 21.8% | 16.4% |
| Headache | 14.1% | 9.3% |
| Sinusitis | 6.3% | 12.9% |
| Arthralgia | 6.3% | 11.4% |
| Back pain | 5.6% | 9.3% |
| Influenza | 3.5% | 9.3% |
| Fatigue | 9.2% | 3.6% |
| Nasopharyngitis | 9.2% | 6.4% |
| Cough | 4.9% | 6.4% |
| Gastroenteritis viral | 2.1% | 6.4% |
| Ligament sprain | 4.2% | 6.4% |
| Migraine | 2.1% | 6.4% |
| Dizziness | 6.3% | 4.3% |
| Abdominal discomfort | 5.6% | 2.9% |
| Dyspepsia | 5.6% | 2.1% |
| Urinary tract infection | 5.6% | 2.1% |
| Muscle strain | 2.1% | 5% |
| Oropharyngeal pain | 1.4% | 5% |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 30.45 | 19.75 |
| On-drug observation period | 33.80 | 19.29 |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 18.11 | 8.92 |
| On-drug observation period | 20.42 | 8.57 |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| 78.73 | 52.70 |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | -9.27(9.22) | -6.91(8.22) |
| On-drug observation period | -10.46(9.22) | -7.24(8.67) |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 3.55(6.98) | 4.21(6.85) |
| On-drug observation period | 4.03(6.49) | 4.77(6.03) |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 13.5(21.4) | 15.5(23.0) |
| On-drug observation period | 15.2(21.4) | 17.5(21.4) |
| Measure | Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|---|
| In-trial observation period | 47(59) | 49(69) |
| On-drug observation period | 53(61) | 51(69) |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| -0.2(0.3) | -0.1(0.2) |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| -4.04(9.59) | -0.28(11.46) |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| -2(14) | -1(13) |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| -1(11) | -1(10) |
| Liraglutide 3.0 mgn=142 | Placebon=140 |
|---|---|
| -0.01(0.59) | 0.00(0.77) |
This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).
Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * BMI above or equal to 30 kg/m\^2 * Male or female, age 18 years or older at the time of signing informed consent Exclusion Criteria: * HbA1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), or diagnosis of type 1 or type 2 diabetes mellitus * Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree or greater heart block * Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine Neoplasia type 2 (MEN2) * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice) * Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics) * History of pancreatitis (acute or chronic) * History of major depressive disorder within the past 2 years * Any lifetime history of a suicide attempt * Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg) * History of malignancy (except for non-melanoma skin cancer) within the past 5 years
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.